Clinical Acumen Versus Androgen Receptor Variant 7 Circulating Tumor Cells in Decision-Making for Men with Advanced Prostate Cancer (European Urology)

In this issue of European Urology, Graf et al [1] provide intriguing information regarding the impact of the constitutively active androgen receptor variant 7 (AR-V7) on outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). In this study, which expands on a substantial body of work from the same authors, they track the use of androgen receptor signaling inhibitors (ARSIs) or taxanes for men with mCRPC past first-line therapy and provide data supporting the idea that the EPIC AR-V7 circulating tumor cell (CTC) assay could have added important information to physicians` decision-making.